Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P13533
UPID:
MYH6_HUMAN
Alternative names:
Myosin heavy chain 6; Myosin heavy chain, cardiac muscle alpha isoform
Alternative UPACC:
P13533; A2RTX1; D9YZU2; Q13943; Q14906; Q14907
Background:
Myosin-6, also known as Myosin heavy chain 6 and Myosin heavy chain, cardiac muscle alpha isoform, plays a pivotal role in muscle contraction. This protein is integral to the heart's ability to pump blood efficiently throughout the body.
Therapeutic significance:
Myosin-6 is implicated in several cardiac disorders, including Atrial septal defect 3, Cardiomyopathy (familial hypertrophic, 14 and dilated, 1EE), and Sick sinus syndrome 3. These conditions highlight the protein's critical role in cardiac health and underscore the potential for targeted therapies to mitigate these serious diseases.